Cargando…

F52. EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY

BACKGROUND: Long-term efficacy and safety data from prospective studies in adolescents with schizophrenia are limited. Lurasidone is an atypical antipsychotic that has demonstrated efficacy in the treatment of schizophrenia in both adults and adolescents. The aim of the current open-label trial was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goldman, Robert, Tocco, Michael, Pikalov, Andrei, Cucchiaro, Josephine, Deng, Ling, Loebel, Antony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888173/ http://dx.doi.org/10.1093/schbul/sby017.583

Ejemplares similares

S73. EFFECT OF LURASIDONE ON COGNITION IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 2-YEAR OPEN-LABEL EXTENSION STUDY
por: Harvey, Philip D, et al.
Publicado: (2018)

T5. LURASIDONE AND RISK FOR METABOLIC SYNDROME IN PATIENTS WITH SCHIZOPHRENIA: A COMPREHENSIVE DATABASE ANALYSIS
por: Tocco, Michael, et al.
Publicado: (2018)

PM413. Metabolic Syndrome in Patients With Schizophrenia Receiving Long-Term Treatment With Lurasidone, Quetiapine XR, or Risperidone
por: Newcomer, John W., et al.
Publicado: (2016)

Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia
por: Meyer, Jonathan M., et al.
Publicado: (2015)

A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia
por: Tandon, Rajiv, et al.
Publicado: (2016)

Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies
por: Nasrallah, Henry A., et al.
Publicado: (2014)

F60. INFLAMMATORY MARKERS AND COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH LURASIDONE
por: Pikalov, Andrei, et al.
Publicado: (2018)

LURASIDONE IN THE LONG‐TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24‐WEEK OPEN‐LABEL EXTENSION STUDY
por: Ketter, Terence A., et al.
Publicado: (2016)

Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study
por: Mattingly, Greg W., et al.
Publicado: (2020)

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study
por: Citrome, Leslie, et al.
Publicado: (2013)

Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia
por: Loebel, Antony D., et al.
Publicado: (2013)

Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment
por: Pikalov, Andrei, et al.
Publicado: (2017)

PM418. Efficacy of Lurasidone in Patients With Schizophrenia With Prominent Positive Symptoms: A Pooled Analysis of Short-Term Placebo-Controlled Studies
por: Potkin, Steven G., et al.
Publicado: (2016)

Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study
por: Goldman, Robert, et al.
Publicado: (2017)

Lurasidone in adolescents with schizophrenia: Sustained remission and recovery during 2 years of open-label treatment
por: Tocco, M., et al.
Publicado: (2021)

Sleep Disturbance, Irritability, and Response to Lurasidone Treatment in Children and Adolescents with Bipolar Depression
por: Singh, Manpreet K., et al.
Publicado: (2023)

Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia
por: Awad, George, et al.
Publicado: (2016)

Lurasidone in Children and Adolescents with Bipolar Depression Presenting with Mixed (Subsyndromal Hypomanic) Features: Post Hoc Analysis of a Randomized Placebo-Controlled Trial
por: Singh, Manpreet K., et al.
Publicado: (2020)

PS37. Lurasidone in the Treatment of Bipolar Depression: Effect of Baseline Depression Severity on Clinical Outcome
por: Pikalov, Andrei, et al.
Publicado: (2016)

Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia
por: Correll, Christoph U., et al.
Publicado: (2022)

Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia
por: Awad, George, et al.
Publicado: (2014)

Tolerability, Safety, and Effectiveness of Two Years of Treatment with Lurasidone in Children and Adolescents with Bipolar Depression
por: DelBello, Melissa P., et al.
Publicado: (2021)

Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies
por: Costamagna, Isabella, et al.
Publicado: (2021)

Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: Pooled analysis of double-blind, placebo-controlled 6-week studies
por: Calisti, F., et al.
Publicado: (2021)

Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression
por: Loebel, Antony, et al.
Publicado: (2015)

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
por: Rajagopalan, Krithika, et al.
Publicado: (2016)

The direct and indirect effects of lurasidone monotherapy on functional improvement among patients with bipolar depression: results from a randomized placebo-controlled trial
por: Rajagopalan, Krithika, et al.
Publicado: (2016)

Change in daytime sleepiness and cognitive function in a 6-month, double-blind study of lurasidone and quetiapine XR in patients with schizophrenia
por: Harvey, Philip D., et al.
Publicado: (2016)

Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials
por: Rajagopalan, Krithika, et al.
Publicado: (2016)

Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
por: Correll, Christoph U., et al.
Publicado: (2021)

Lurasidone for the Treatment of Irritability Associated with Autistic Disorder
por: Loebel, Antony, et al.
Publicado: (2015)

Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis
por: Newcomer, John W., et al.
Publicado: (2018)

Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
por: Iyo, Masaomi, et al.
Publicado: (2021)

M48. IS METABOLIC SYNDROME RELATED TO COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA? RESULTS FROM A DOUBLE-BLIND, ACTIVE-CONTROLLED, LURASIDONE STUDY
por: Hagi, Katsuhiko, et al.
Publicado: (2020)

S5. DOES THE TIME OF DRUG ADMINISTRATION ALTER THE ADVERSE EVENT RISK OF LURASIDONE?
por: Hagi, Katsuhiko, et al.
Publicado: (2020)

Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis
por: Arango, Celso, et al.
Publicado: (2019)

Effectiveness of Lurasidone 80 mg in Patients with Schizophrenia: Results of an Open-Label, 12-Week Extension Study
por: Miura, Itaru, et al.
Publicado: (2022)

Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US
por: O’Day, Ken, et al.
Publicado: (2013)

Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation
por: Loebel, Antony, et al.
Publicado: (2015)

Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study
por: Patel, Preeya J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v07risgebe004t75tdkrug57uo